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Background: Despite a class IIa indication for Digoxin use in
heart failure by both ACC/AHA and ESC, its use has been going
down in the last decade. One of the reasons has been the
result of The Digitalis Investigation Group (DIG) Trial. This
randomized controlled study in 6800 patients of ambulatory
heart failure (age 21 yrs, LV ejection fraction 45%, normal
sinus rhythm) failed to show a mortality benefit from Digoxin
use. It did however demonstrate a reduction in hospitaliza-
tions overall and for worsening heart failure.
Objectives: Since more than half of these heart failure
patients had high risk features characterized by class IIIeIV
symptoms, or ejection fraction lower than 25% or with a CT
ratio more than 55% a subanalysis of DIG Trial data was
planned to see the effect of Digoxin in this subcategory in
terms of the composite endpoints of mortality or hospitali-
zations over 2 years.
Patients and methods: From the dataset of DIG patients
obtained from the National Heart Blood and Lung Institute,
4367 high risk patients (mean age 64 years, 26% females) were
analyzed. There were 2223 (51%) with class IIIeIV symptoms,
2256 (52%) with LVEF<25%, and 2345 (54%) with CTR>55%. All
high risk feature groups were analyzed separately and also
together.
Pearson chi square andWicoxon rank sum tests showed no
significant difference in the baseline characteristics, including
medical history, cause of heart failure and drug use between
the three groups (except that dyspnea was more in the those
with class IIeIV symptoms). Outcomes were assessed using
Kaplan Meier and Cox proportional hazard analyses. Statis-
tical analysis was two tailed in all cases and a p value of <0.05
was considered significant.
Results: Results at 24 months showed that all-cause
mortality or all-cause hospitalization was significantly better
with Digoxin use versus placebo. Hazard ratio for NYHA class
IIIeIV was 0.88 (p ¼ 0.012); 0.84 (p ¼ 0.001) for LVEF <25% and
0.85 (p ¼ 0.002) for those with CTRs >55%, absolute risk
reduction being2%,6% and4% respectively. Therewas an
absolute risk reduction of 3% in favor of Digoxin if any of the
three high risk feature was present (p  0.001). Also, signifi-
cantly less patients receiving Digoxin experienced heart
failure related mortality or hospitalization. HR was 0.65
(p< 0.001) for NYHA class IIIeIV; 0.61 (p< 0.001) for LVEF<25%
and 0.65 (p < 0.001) for CTRs >55%(absolute risk reductionof 11%, 12%, 11%, 10% respectively and 11% when any
of the high risk features were present; p ¼ 0.001).
Conclusion: Digoxin use reduced the primary endpoint of
all-cause and heart failure mortality or hospitalizations in
high risk heart failure patients. This effect was primarily
driven by reduction in hospitalizations with no significant
effect on mortality.
Implications
Heart failure hospitalization is plagued not only by increasing
mortality but also by high rates of repeated admissions
(15e30% within 60e90 days of discharge). This has socioeco-
nomic implications and can be addressed with Digoxin. This
being an inexpensive and relatively safe drug could be used in
those patients where severe signs and symptoms persist after
hospitalization for heart failure.
This above discussed substudy as with the parent DIG trial
did not report mortality benefit. One of the reasons implicated
is a possible increased serum concentrations of Digoxin that
adversely affected the outcomes. Moreover patients in this
trial did not receive either Beta-blockers or Aldosterone
antagonists which affect outcomes and are recommended in
the present HF guidelines. Whether the finding of this trial
that did not have an Asian population can be applied fully in
the Indian context is also an issue. Lastly the question of
Digoxin use in heart failurewith preserved LVEF remains open
for investigation.
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Clinical perspective
The TARGET study attempts to improve outcomes in patients
undergoing cardiac resynchronization therapy (CRT). Identi-
fying the latest site of left ventricular (LV) contraction by
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site for lead placement was thought to result in better
synchronization and outcomes.
As compared to the conventional site of LV pacing using
anatomic guide, the speckle-tracking guided pacing resulted
in a higher responder rates both in terms of LV size regression
and clinical end-points such as NYHA class and combined all-
cause mortality and heart failure hospitalizations.
However this study has many limitations: (1) speckle-
tracking radial strain imaging is neither the best nor the
final word in locating the last activation of LV; (2) small sample
sizewith limited follow-up of 6months fromonly 2 centres; (3)
so-far all echocardiographic studies to guide CRT has had
significant inter-observer variability and could not predict
outcomes (PROSPECT). Echo studies using advanced software
lack reproducibility, requires trained personnel and not
readily available for mass practical implementation; (4) in
almost one-third patients the targeted site could not be paced
because of inaccessible venous anatomy and or presence
of scar.
Nonetheless this study is a step-forward in establishing the
fact that if we can identify & pace the “sweet-spot” in the LV,
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Context: The benefit of aspirin for the primary prevention
of cardiovascular events is relatively small for individuals
with and without diabetes. This benefit could easily be offset
by the risk of hemorrhage.
Objective: To determine the incidence of major gastroin-
testinal and intracranial bleeding episodes in individuals with
and without diabetes taking aspirin.
Design, setting, and participants: A population-based
cohort study, using administrative data from 4.1 million citi-
zens in 12 local health authorities in Puglia, Italy. Individuals
with new prescriptions for low-dose aspirin (300 mg) were
identified during the index period from January 1, 2003, to
December 31, 2008, and were propensity-matched on a 1-to-1
basis with individuals who did not take aspirin during this
period.
Main outcome measures: Hospitalizations for major
gastrointestinal bleeding or cerebral hemorrhage occurring
after the initiation of antiplatelet therapy.
Results: There were 186,425 individuals being treated with
low-dose aspirin and 186,425 matched controls without
aspirin use. During amedian follow-up of 5.7 years, the overall
incidence rate of hemorrhagic events was 5.58 (95% CI,
5.39e5.77) per 1000 person-years for aspirin users and 3.60
(95% CI, 3.48e3.72) per 1000 person-years for those withoutaspirin use (incidence rate ratio [IRR], 1.55; 95% CI, 1.48e1.63).
The use of aspirin was associated with a greater risk of major
bleeding in most of the subgroups investigated but not in
individuals with diabetes (IRR, 1.09; 95% CI, 0.97e1.22). Irre-
spective of aspirin use, diabeteswas independently associated
with an increased risk of major bleeding episodes (IRR, 1.36;
95% CI, 1.28e1.44).
Comments
In a population-based cohort, aspirin use was significantly
associated with an increased risk of major gastrointestinal or
cerebral bleeding episodes. Patients with diabetes had a high
rate of bleeding that was not independently associated with
aspirin use.
A meta-analysis based on individual patient data demon-
strated that the benefits of low-dose aspirin for the primary
prevention of cardiovascular disease are modest. Any benefit
of low-dose aspirin might be offset by the risk of major
bleeding. It is known that aspirin is associated with gastro-
intestinal and intracranial hemorrhagic complications.
Observational studies suggest an excess of approximately 1e2
major bleeding episodes annually for every 1000 patients
treated with low doses of aspirin. The bleeding risk sharply
increases in individuals older than 70 years. The bleeding rate
was five times higher than the bleeding rate expected based
on the results of previously published randomized clinical
trials. Diabetics had 36% increased risk of major bleeding
episodes irrespective of aspirin use. So, when we have to
balance the risk and benefits of aspirin, we have to remember
that the baseline risk of bleeding can be very high in some
subgroups of patients.
But this study, for the first time, to our knowledge, showed
that aspirin therapy only marginally increases the risk of
bleeding in individuals with diabetes. The incidence rate of
major bleeding was 5.35 per 1000 person-years in those who
never took aspirin compared with 5.83 among those taking
low-dose aspirin, a nonsignificant difference.
These results can represent indirect evidence that the
efficacy of aspirin in suppressing platelet function is reduced
in this population. An accelerated platelet turnover in dia-
betes could explain the reduced incidence of adverse effects
related to aspirin, as well as its limited efficacy in preventing
major cardiovascular events.
So finally, weighing the benefits of aspirin therapy against
the potential harms is of particular relevance in the primary
prevention setting, in which benefits seem to be lower than
expected based on results in high-risk populations. In this
population-based cohort, aspirin use was significantly asso-
ciated with an increased risk of major bleeding, but this
association was not observed for patients with diabetes. In
this respect, diabetes might represent a different population
in terms of both expected benefits and risks associated with
antiplatelet therapy.
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